Prednisone Use and Risk of Mortality in Patients with Rheumatoid Arthritis: Moderation by Use of Disease-Modifying Antirheumatic Drugs

Arthritis Care and Research

Volumn 68, Issue 5, 2016, Pages 706-710

  Chester Wasko, Mary ^a   Dasgupta, Abhijit ^b   Ilse Sears, Genevieve ^a   Fries, James F ^c   Ward, Michael M ^b  

^a ALLEGHENY HEALTH NETWORK   (United States)

^b NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; DRUG USE; FEMALE; FOLLOW UP; HAZARD RATIO; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; OBSERVATIONAL STUDY; PROPENSITY SCORE; PROSPECTIVE STUDY; RANDOM FOREST; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; ADVERSE DRUG REACTION; AGED; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TIME FACTOR;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONG TERM ADVERSE EFFECTS; MALE; METHOTREXATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDNISONE; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; SULFASALAZINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84964523885     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22722     Document Type: Article

References (15)

1. Kirwan JR, and the Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 1995; 333: 142-6.
2. Mikuls TR, Fay BT, Michaud K, Sayles H, Thiele GM, Caplan L, et al., Associations of disease activity and treatments with mortality in men with rheumatoid arthritis: results from the VARA registry. Rheumatology (Oxford) 2011; 50: 101-9.
3. Caplan L, Wolfe F, Russell AS, Michaud K., Corticosteroid use in rheumatoid arthritis: prevalence, predictors, correlates, and outcomes. J Rheumatol 2007; 34: 696-705.
4. Del Rincon I, Battafarano DF, Restrepo JF, Erikson JM, Escalante A., Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheumatol 2014; 66: 264-72.
5. Wasko MC, Dasgupta A, Hubert H, Fries JF, Ward MM., Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis. Arthritis Rheum 2013; 65: 334-42.
6. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al., The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
7. Fries JF, Spitz PW, Young DY., The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 1982; 9: 789-95.
8. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F., Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359: 1173-7.
9. Sugihara M., Survival analysis using inverse probability of treatment weighted methods based on the generalized propensity score. Pharm Stat 2010; 9: 21-34.
10. Breiman L., Random forests. Machine Learning 2001; 45: 5-32.
11. Lee BK, Lessler J, Stuart EA., Improving propensity score weighting using machine learning. Stat Med 2010; 29: 337-46.
12. Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B, et al., Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994; 96: 115-23.
13. Bollet AJ, Black R, Bunim JJ., Major undesirable side-effects resulting from prednisolone and prednisone. JAMA 1955; 158: 459-63.
14. Truhan AP, Ahmed AR., Corticosteroids: a review with emphasis on complications of prolonged systemic therapy. Ann Allergy 1989; 62: 375-91.
15. Davis JM III, Maradit-Kremers H, Gabriel SE., Use of low-dose glucocorticoids and the risk of cardiovascular morbidity and mortality in rheumatoid arthritis: what is the true direction of effect? J Rheumatol 2005; 32: 1856-62.